Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Merck Serono’s Erbitux Extends Survival by 7.5 Months

By R&D Editors | September 30, 2013

Merck KGaA announced that the German cooperative investigator group AIO (Arbeitsgemeinschaft Internistische Onkologie) reported new data from the Phase 3 head-to-head clinical trial FIRE-3, which show a clinically relevant improvement from Erbitux (cetuximab) plus FOLFIRI versus bevacizumab plus FOLFIRI as first-line treatment in metastatic colorectal cancer (mCRC) in patients with RAS wild-type tumors.
 
The new data, from a preplanned exploratory analysis, were presented at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO). The analysis shows a 7.5 month increase in median overall survival (OS) in mCRC patients with RAS wildtype tumors, receiving first-line Erbitux plus FOLFIRI compared with patients receiving bevacizumab plus FOLFIRI (OS: 33.1 months vs. 25.6 months, respectively). In a post hoc analysis of the patient group with any RAS mutations, patients who received Erbitux plus FOLFIRI first-line reached an OS of 20.3 months vs. 20.6 months in the group that was treated with bevacizumab plus FOLFIRI.
 
As previously presented at the annual meeting of the American Society of Clinical Oncology (ASCO) 2013 and at the World Congress on Gastrointestinal Cancer 2013, the primary endpoint of the trial, objective response rate based on investigators’ read in patients with KRAS exon 2 wild-type tumors, was not met. In the patient group with KRAS exon 2 wild-type tumors, an expected and balanced cross-over or continuation beyond progression with regard to subsequent biologic treatments in second line therapy (either EGFR antibody or bevacizumab) was observed. Also, no major imbalances were noted with regard to chemotherapies used in second line treatment. It is important to note that this result is not fully mature (57 percent event rate in the “intent-to-treat” KRAS exon 2 wild-type population) and will be updated in due course.
 
“These new data from the Phase 3 study FIRE-3 show a 7.5-month increase in median overall survival to 33.1 months when using first-line Erbitux plus FOLFIRI as compared to using bevacizumab plus FOLFIRI in metastatic colorectal cancer. Such a prolongation is a paradigm shift in mCRC treatment since the introduction of monoclonal antibodies,” said Professor Volker Heinemann from the Ludwig Maximilians University, Munich, and FIRE-3 principal investigator. “Together with insights from other recent relevant studies, these results suggest that first-line treatment of RAS wild-type patients should include an anti-EGFR therapy.”
 
“These results continue to reinforce the value of Erbitux as a first-line treatment for metastatic colorectal cancer and show that RAS tumor status is likely to help to identify those patients who are most likely to benefit from Erbitux,” said Dr. Annalisa Jenkins, head of Global Drug Development and Medical at the Merck Serono division. “Additional biomarker analyses are being conducted on data from the pivotal Erbitux studies, CRYSTAL and OPUS to help shed additional light on the role of RAS mutations in these patients.”
 
Date: September 28, 2013
Source: Merck KGaA

Related Articles Read More >

2025 R&D layoffs tracker tops 92,000
Health-related innovation in Morocco highlighted by resident inventor patenting activity
ARPA-H funds $29M Ginkgo-led project to reshore pharma supply chains using wheat germ tech
DNA microscope offers new 3D view of organisms from the inside out
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE